Validation of the PRIMA-Prognostic Index for Patients Treated with Rituximab Plus Chemotherapy and Refinement of Prognostic Parameters for Patients on Rituximab Plus Lenalidomide in the Phase III Relevance Trial

Affiliation auteursAffiliation ok
TitreValidation of the PRIMA-Prognostic Index for Patients Treated with Rituximab Plus Chemotherapy and Refinement of Prognostic Parameters for Patients on Rituximab Plus Lenalidomide in the Phase III Relevance Trial
Type de publicationJournal Article
Year of Publication2019
AuteursJulia E, Fowler NH, Bachy E, Feugier P, Bouabdallah R, Tilly H, M. Palomba L, Fruchart C, , Casasnovas R-O, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, Bouabdallah K, Brice P, Ribrag V, Daguindau N, Le Gouill S, Pica G-M, Martin A, Lopez-Guillermo A, Larouche J-F, Ando K, Maria Gda Silva, Andre M, Wu KLung, Sehn LH, Tobinai K, Cartron G, Delarue R, Czuczman M, Xerri L, Salles GA, Morschhauser F
JournalBLOOD
Volume134
Date PublishedNOV 13
Type of ArticleMeeting Abstract
ISSN0006-4971
DOI10.1182/blood-2019-129024